Cortex Pharmaceuticals Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. The company reported a net loss applicable to common stock of $3,243,000 or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000 or $0.07 per share for the corresponding prior year period. The company reported loss from operations of $1,729,000 compared to $3,231,000 for the same period a year ago. For the nine months ended September 30, 2009, the company reported a net loss applicable to common stock of $9,189,000 or $0.18 per share compared to a net loss applicable to common stock of $11,466,000 or $0.24 per share for the corresponding prior year period. Non-cash charges for the nine months ended September 30, 2009 and 2008 approximated $2,803,000 and $1 063,000, respectively. The company reported loss from operations of $6,860,000 compared to $11,866,000 for the same period a year ago.

Cortex Pharmaceuticals Inc. expected to Report Q3 2009 Results on November 9, 2009. This event was calculated by Capital IQ (Created on November 5, 2009).

Cortex Pharmaceuticals Inc. announced that at its EGM on November 23, 2009, the shareholders will consider the approval of an amendment to the company's restated certificate of Incorporation to increase the authorized number of shares of the company's common stock from 105,000,000 to 205,000,000, which is critical for financing the continuing operations of the company, as well as potential corporate partnering arrangements that may include an equity position in the company as part of such agreement.